Table 3.

Overview of AEs in all patients who received furmonertinib 160 mg monotherapy or combination therapy as subsequent treatment

Adverse events	Grade 1	Grade 2	Grade 3	Grade 4
	n (%)	n (%)	n (%)	n (%)
General Disorders
Fatigue	2 (7.1)		1 (3.6)
Decreased appetite	2 (7.1)		1 (3.6)
Hematologic toxicity
Leukopenia	3 (10.7)	1 (3.6)		1 (3.6)
Anemia	5 (17.9)	2 (7.1)
Decrased platelet count				1 (3.6)
Gastrointestinal toxicity
Mucositis oral			1 (3.6)
Diarrhea		1 (3.6)
Renal toxicity
Increased serum creatinine		2 (7.1)
Metabolism disorders
Hypocalcemia			1 (3.6)
Hepatobiliary toxicity
Increased ALT/AST	4 (14.3)		1 (3.6)

n number, AEs adverse events, ALT alanine aminotransferase, AST aspartate aminotransferase